ClinicalTrials.gg
Not yet recruitingNCT07493577iSPASM-2Updated Nov 4, 2026

Induced Suppression of Platelet Activity in Aneurysmal Subarachnoid Hemorrhage Management-2 (iSPASM-2)

A Phase 1/2 interventional study of Tirofiban and Placebo in Aneurysmal Subarachnoid Hemorrhage, sponsored by Dr David Hasan, M.D.. Not yet recruiting at 2 sites in United States. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-11-04.

Sponsored by Dr David Hasan, M.D. · Phase 1/2, Interventional, and Treatment

How we know

Updated Nov 4, 2026Start date movedPrimary completion moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
82
Allocation
Randomized
Ages
18 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 149 studies in Subarachnoid Hemorrhage with a site in United States — 31 open to participants now, 37 under way, 2 of them phase 3. Subarachnoid Hemorrhage · United States.

Planned enrollment
28th of 107
82 · median 30
Started
2026
with 7 others
Phase 1/2
13 of 149
1 open now
Primary completion
2029-05
later than 31 of 36 live
Registered
145th of 149
by date

Among the 149 studies in Subarachnoid Hemorrhage with a site in United States, this one is the 28th largest by planned enrollment of the 107 interventional ones that give a count, is one of 8 that started in 2026, is one of 13 in phase 1/2, reaches primary completion later than 31 of the 36 other live ones, and was the 145th registered.

Subarachnoid Hemorrhage

513 studies on the registry are indexed under Subarachnoid Hemorrhage; 131 are open to participants now.

Browse Subarachnoid Hemorrhage studies →

Open to participants now

31 of the 149 studies in Subarachnoid Hemorrhage with a site in United States are open now. Recruiting first, the newest first:

26 more — sign in →

All 31 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 92 Subarachnoid Hemorrhage studies recruiting now, 58 (63%) set no upper age limit and 5 (5%) stop at 75 or younger; 8 take children under 18; 8 take healthy volunteers.

This study: 18 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 149 studies in Subarachnoid Hemorrhage with a site in United States, or all of them as a file.
02

Study summary

An exploratory, randomized, double-blinded, placebo-controlled, two-center clinical trial to determine the maximum tolerated dosage of intravenous tirofiban in patients with aneurysmal subarachnoid hemorrhage (aSAH) post-endovascular coiling. The study will also assess pharmacology and safety, with exploratory endpoints including delayed cerebral ischemia (DCI), vasospasm, and functional outcomes.

Read the detailed description

This is an exploratory, two-center, randomized, double-blinded study. The primary objective is to determine the maximum tolerated dosage (MTD) of tirofiban in the context of patients with aSAH status post-endovascular coiling. The dosage regimen of tirofiban will be 0.10µg/kg/min (actual weight) within 48 hours of aneurysm securing and within 72 hours of ictus.

The study will involve a dose escalation stage and a cohort expansion stage. During the dosage-escalation stage, the intervention doses include continuous intravenous (IV) tirofiban or IV placebo for 1 day, 3 days, 5 days, or 7 days. Dose-escalation will follow the time-to-event Bayesian Optimal Intervention (TITE-BOIN) design. Unlike the majority of existing phase I designs, which require suspending the accrual after treating each cohort of patients, the TITE-BOIN design allows for real-time dose assignment decisions for new patients while the toxicity data are still pending for some patients under treatment. This shortens the trial duration and reduces the logistical difficulties caused by frequent suspensions of accrual. For parallel comparison under real-world conditions, patients will be randomly assigned to tirofiban and placebo in a 2:1 ratio in the dose escalation stage. The data from the placebo patients will not be analyzed to inform dose escalation but included in the final analysis upon study completion. Upon the completion of the dose escalation stage, the MTD will be selected using isotonic regression. MTD will be selected as the dosage for which the isotonic estimate of the toxicity rate is closest to the target dosage-limiting toxicity rate (30%). If there is a tie, we will select the higher dosage level when the isotonic estimate is lower than the target toxicity rate, and we will select the lower dosage level when the isotonic estimate is greater than or equal to the target toxicity rate.

During the cohort expansion stage, patients will be randomized to tirofiban at MTD and placebo at the corresponding dosage level to achieve balanced sample sizes (30 tirofiban at MTD and 30 placebo for any infusion duration, combined from both phases) across the two groups. The analysis of the exploratory endpoints will be performed on the tirofiban patients at MTD and placebo patients with any infusion duration.

An interim pharmacokinetic (PK) analysis will be performed after 10 evaluable patients are treated with tirofiban to determine possible dose modification. At the completion of the study, PK and pharmacodynamic (PD) analysis will be conducted using all evaluable patients treated with tirofiban to determine whether augmented renal clearance in aSAH interacts with the pharmacokinetics and pharmacodynamics of tirofiban.

03

Conditions studied

  • Aneurysmal Subarachnoid Hemorrhage

Keywords

  • Subarachnoid Hemorrhage
  • Delayed Cerebral Ischemia
  • Tirofiban
  • Brain Aneurysm Rupture
04

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 18-85
  • Baseline Modified Rankin Scale (mRS) 0-3 (pre-SAH)
  • SAH attributed to ruptured cerebral aneurysm
  • Admission Computed Tomography (CT) scan shows Modified Fisher grade 1-4 due to aSAH primarily in the supratentorial space
  • World Federation of Neurosurgical Societies (WFNS) scale grade ≤4 at randomization
  • Onset of symptoms of aSAH (ictus) occurred \<72 hours prior to presentation
  • If External Ventricular Drain (EVD) placed, placement is ≥12 hours prior to enrollment
  • All aneurysm(s) suspected to be responsible for the hemorrhage must be secured via Endovascular Coil Embolization with a post-embolization Raymond-Roy Score of 1 (Complete) or 2 (Residual Neck) prior to enrollment
  • Participant can be randomized within 48 hours of aneurysm treatment
  • Participant or participant's legally-authorized representative (LAR) has provided documented

Exclusion criteria

Exclusion:

  • Angio-negative SAH, defined as a SAH with a digital subtraction angiogram that does not show an intracranial aneurysm
  • Surgical clipping prior of the ruptured aneurysm or any non-ruptured aneurysm on the same admission to enrollment
  • Remaining untreated aneurysm(s) that could reasonably be considered a possible alternate cause of the aSAH based on the observed bleeding pattern
  • Uncontrollable hypertension (>180 systolic and/or >110 diastolic) that is not correctable prior to enrollment
  • Active internal bleeding, or history of bleeding diathesis, major surgical procedure, or severe physical trauma within the previous month (30 days)
  • A medical diagnosis that requires continuous use of aspirin, clopidogrel, ticagrelor, or tirofiban during the study drug infusion
  • New parenchymal hemorrhage or new infarction larger than 15 cubic centimeters (cc) in volume by CT
  • Thrombolytic therapy within 24 hours prior to enrollment (alteplase, tenecteplase, or urokinase)
  • Previous intracranial hemorrhage, intracranial neoplasm, subarachnoid hemorrhage, or arterial-venous malformation
  • Thrombocytopenia ( count \<100,000/microliter (µL) assuming clumping is ruled out
  • Allergy or intolerance to tirofiban
  • Pregnant or lactating
  • Chronic kidney disease with (CrCl ≤ 30 milliliters per minute [ml/min]) or acute kidney injury (AKI) at study screening. AKI is defined as:

    i) Increase in serum creatinine by 0.3 milligrams per deciliter (mg/dL) or more (26.5 micromoles per liter [μmol/L] or more) within 48 hour period; OR ii) Increase in serum creatinine to 1.5 times or more than the baseline of the prior 7 day period; OR iii) Urine volume less than 0.5 ml/kg/hour for at least 6 hours

Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
82 participants (estimated)

Study arms

  • Experimental
    Tirofiban

    Continuous IV infusion of tirofiban for 1, 3, 5, or 7 days post-endovascular coiling.

    Drug: Tirofiban

  • Placebo comparator
    Placebo

    Continuous IV infusion of saline placebo for 1, 3, 5, or 7 days post-endovascular coiling.

    Drug: Placebo

Interventions

  • IV infusion at 0.10 microgram/kilogram/minute (mcg/kg/min) for 1 day, 3 days, 5 days, or 7 days according to the dose escalation procedure.

    Also known as: Aggrastat ®

  • DrugPlacebo

    IV infusion at the same infusion duration as the study drug; same adjustments

    Also known as: Normal Saline

06

What researchers measure

Primary outcomes

  1. Tirofiban dosage-limiting toxicity (DLT)

    Presence of any of the following: any intracranial hemorrhage, major extracranial hemorrhage (defined as clinically overt bleeding leading to death; OR clinically overt bleeding causing a reduction in hemoglobin of ≥2g/dl; OR clinically overt bleeding necessitating transfusion of ≥2 units of packed red cells or whole blood; OR clinically overt bleeding in a critical area or organ other than the intracranial compartment (including intraspinal, intraocular, pericardial, intra-articular, retroperitoneal, intramuscular \[with compartment syndrome\])), thrombocytopenia, or serious adverse event (SAE) due to tirofiban.

    Time frame: Within 14 days post-randomization

Secondary outcomes

  1. Pharmacokinetic parameters - total clearance (Cltot)

    Time frame: Up to 7 hours after drug discontinuation

  2. Pharmacokinetic parameters - Volume of distribution (Vd)

    Time frame: Up to 7 hours after drug discontinuation

  3. Pharmacokinetic parameters - Maximum (peak) plasma concentration (Cmax)

    Highest concentration of tirofiban in the blood after a dose is administered

    Time frame: Up to 7 hours after drug discontinuation

  4. Pharmacokinetic parameters - Minimum (trough) plasma concentration (Cmin)

    Lowest observed concentration of tirofiban in the blood after a dose is administered

    Time frame: Up to 7 hours after drug discontinuation

  5. Pharmacokinetic parameters - Average Plasma Concentration (Cavg)

    Average tirofiban concentration in the blood at steady state

    Time frame: Up to 7 hours after drug discontinuation

  6. Pharmacokinetic parameters - Area Under the Concentration (AUC)Time Curve

    Area under the curve from time 0 extrapolated to infinite time

    Time frame: Up to 7 hours after drug discontinuation

  7. Pharmacodynamic parameters - adenosine diphosphate (ADP)

    The percent inhibition of ADP-induced platelet aggregation

    Time frame: Baseline, 2, 6, and every 24 hours and at drug cessation

Other outcomes

  1. Delayed cerebral ischemia (DCI) or death without DCI

    This is the primary exploratory efficacy outcome, which is a composite binary outcome. DCI is defined as any of the following: a. Focal neurological impairment, b. decrease of at least 2 points on the Glasgow coma scale and/or c. cerebral infarction present on final CT or MRI, which was not present on a CT or MRI between 24-48 hours post-endovascular therapy and not attributable to other causes.

    Time frame: Within 14 days post-randomization

  2. Cerebral vasospasm

    Cerebral vasospasm requires confirmation of vasospasm on either CTA or DSA confirming mild vasospasm (decrease in vessel diameter by ≤25% of normal artery diameter), moderate vasospasm (decrease in vessel diameter by \>25 to ≤50% of normal diameter but cerebral vasospasm), or severe vasospasm (decrease in vessel diameter by \>50% of normal vessel diameter)

    Time frame: Within 14 days post-randomization or until discharge from the index admission, which occurred later

  3. Mortality

    Death of any cause

    Time frame: 3 and 6 months post-randomization

  4. Total number of days in the ICU for the index admission

    Total number of days from ICU admission to ICU discharge during the index hospitalization

    Time frame: Up to 6 months post-randomization

  5. Total hospital stay length for the index admission

    Total number of days from admission to discharge during the index admission

    Time frame: Up to 6 months post-randomization

  6. Modified Rankin Scale (mRS)

    It is a clinician-reported measure of global disability, widely applied for evaluating stroke patient outcomes and as an endpoint in randomized clinical trials. It is a single-item 7-point scale with a range of 0 (no symptoms at all) to 6 (death), with higher scores indicating greater disability. The elements of the mRS are as follows: (1) no symptoms at all; (2) no significant disability, but there may be slight symptoms such as weakness or numbness; (3) slight disability, but able to carry out daily activities independently; (4) moderate disability, requiring some help with daily activities; (5) moderately severe disability, requiring assistance with most daily activities; (6) severe disability, bedridden and requiring constant nursing care; and (7) death.

    Time frame: 3 and 6 months post-randomization

  7. Return to work

    Returned to prior level of responsibilities at work

    Time frame: 3 and 6 months post-randomization

  8. Lawton Instrumental Activities of Daily Living (Lawton IADL)

    It is an instrument to assess independent living skills among older adults, and can be used in community or hospital settings. There are 8 domains of function measured with the scale: (1) using the telephone; (2) shopping; (3) preparing food; (4) housekeeping; (5) doing laundry; (6) using transportation; (7) handling medications; (8) handling finances. Women are scored on all 8 areas of function; historically, for men, the areas of food preparation, housekeeping, and laundering are excluded. Individuals are scored according to their highest level of functioning in that category. A summary score ranges from 0 (low function, dependent) to 8 (high function, independent) for women, and 0 through 5 for men.

    Time frame: 3 and 6 months post-randomization

  9. Quality of Life in Brain Injury - Overall Scale (QOLIBRI-OS)

    It is a 6-item scale to evaluate the overall satisfaction with facets of life relevant to people with traumatic brain injury. The area covered by the questionnaire includes physical condition, cognition, emotions, function in daily life, personal and social life, and current situation and future prospects. Responses to each item were scored 1 ('Not at all') to 5 ('Very'), and the sum of all items was converted arithmetically to a percentage scale, with 0 representing the lowest possible (health-related quality of life (HRQoL) on the questionnaire and 100 the best possible HRQoL.

    Time frame: 3 and 6 months post-randomization

  10. Glasgow Outcome Scale-Extended (GOS-E)

    It is used to assess global outcomes in persons with brain injury, by categorizing global function using an 8-point ordinal scale that focuses on disability and functioning in daily life. The scales are: 1. Dead, 2. Vegetative State, 3. Lower Severe Disability (SD), 4. Upper SD, 5. Lower Moderate Disability (MD), 6. Upper MD, 7. Lower Good Recovery (GR), 8. Upper GR

    Time frame: 3 and 6 months post-randomization

  11. PROMIS-29+2

    The Patient-Reported Outcomes Measurement Information System® (PROMIS) is a flexible set of tools designed to measure self-reported physical, mental, and social health and wellbeing. PROMIS-29+2 is a collection of 4-item Likert-item short forms assessing the following domains: 1. Physical function 2. Anxiety 3. Depression 4. Fatigue 5. Sleep disturbance 6. Ability to participate in social roles and activities 7. Pain interference 8. Cognitive Function - Abilities (2 items) 9. Pain intensity (single item) Norm-based scores will be calculated for each domain on the PROMIS measures, so that a score of 50 represents the mean or average of the reference population. A score of 60 means that the person is one standard deviation above the reference population (standard deviation = 10). For PROMIS measures, higher scores equal more of the concept being measured (e.g., more Fatigue, more Physical Function).

    Time frame: 3 and 6 months post-randomization

  12. Montreal Cognitive Assessment (MoCA)

    It is a 30-point test to assess people for dementia. The MoCA evaluates different types of cognitive abilities, including orientation, short-term memory / delayed recall, executive function / visuospatial ability, language ability, abstraction, animal naming, attention, and clock-drawing. Scores range from 0 to 30, with a score of 26 or higher considered normal.

    Time frame: 3 and 6 months post-randomization

07

Study locations

2 sites
  • Duke University Health System
    Durham, North Carolina 27710, United States
  • University of Texas Health Sciences Center
    Houston, Texas 77030, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Start is estimated for Dec 2026; primary completion for May 2029, 29 months later.

Start moved twice since we started tracking on Sep 25, 2026: Jul 2026 → Dec 2026, last on Nov 4, 2026.

Primary completion moved once since we started tracking on Sep 25, 2026: Jan 2029 → May 2029, on Oct 19, 2026.

Completion moved once since we started tracking on Sep 25, 2026: Jan 2032 → May 2032, on Oct 19, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Mar 10, 2026
First posted
Mar 25, 2026
StartEst.
Dec 5, 2026was Jul 2026
Primary completionEst.
May 5, 2029was Jan 2029
CompletionEst.
May 5, 2032was Jan 2032
Last update
Nov 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Jul 23, 2026→Dec 5, 2026
moved 2 times, Oct 19, 2026 – Nov 4, 2026
Primary completion
Jan 23, 2029→May 5, 2029
Oct 19, 2026
Study completion
Jan 23, 2032→May 5, 2032
Oct 19, 2026
Show all 2 updates
  1. Nov 4, 2026
    Start date Nov 5, 2026→Dec 5, 2026
    + 1 other change: verification date
  2. Oct 19, 2026
    Start date Jul 23, 2026→Nov 5, 2026
    Primary completion Jan 23, 2029→May 5, 2029
    Study completion Jan 23, 2032→May 5, 2032
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07493577
Lead sponsor
Dr David Hasan, M.D.
Responsible party
Dr David Hasan, M.D. (Professor of Neurosurgery, Duke University) — Sponsor-investigator
First posted
Mar 25, 2026
Start date
Dec 5, 2026 (estimated)
Primary completion
May 5, 2029 (estimated)
Completion
May 5, 2032 (estimated)
Last update
Nov 4, 2026

Study contacts

Hazani Benitez-Rosas
Contact
hazani.benitez-rosas@duke.edu
919-681-4974
Beth Perry
Contact
beth.perry@duke.edu
919-681-2695
Emad Hasan, MD
principal investigator · Duke University
Brian Mac Grory, MD
principal investigator · Duke University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tirofiban

Start the discussion